(Stroke. 2000;31:2920.)
© 2000 American Heart Association, Inc.
Original Contribution |
Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
A Canadian Hospital’s Experience
From the Division of Neurology (K.M.C., A.R.W., D.C.C.J., J.B., P.A.T.), the Department of Radiology (D.G.), and the Department of Medicine (M.S.), Vancouver Hospital and Health Sciences Center, University of British Columbia, Vancouver, Canada.
Background and Purpose—In the United States, tissue plasminogen activator (tPA) was approved for treatment of acute ischemic stroke in 1996. Its use has only recently been approved in Canada. We sought to evaluate the safety, feasibility, and efficacy of treatment in a Canadian hospital setting.
Methods—A combined retrospective and prospective review is presented of 46 consecutive patients treated with intravenous tPA at our hospital with a treatment protocol similar to that of the National Institute of Neurological Disorders and Stroke (NINDS) trial.
Results—Symptomatic intracranial hemorrhage at 36 hours occurred in 1 patient (2.2%). The median time to treat was 165 minutes, with a median "door-to-needle" time of 84 minutes. Compared with patients presenting initially at our hospital, patients transferred from another institution for tPA therapy were treated closer to the 3-hour time window (mean 173 versus 148 minutes, P<0.001) but had a shorter door-to-needle time (43 versus 102 minutes, P<0.001). For every 10 minutes closer to the 3-hour time window that any patient arrived at the hospital, 7 minutes was saved in the door-to-needle time (correlation coefficient 0.9, P<0.001). Patient outcome did not differ from that in the NINDS trial (P>0.75).
Conclusions—Our safety and patient outcome data compare favorably with NINDS and Phase IV data. Although a 3-hour treatment window was feasible, the median door-to-needle time lengthened as more treatment time was available and the door-to-needle time was beyond recommended standards. This review has prompted changes in our community to improve treatment efficiency.
Key Words: Canada • stroke, ischemic • thrombolytic therapy
This article has been cited by other articles:
 |
|
 |
|
  M. Reeves, A. Bhatt, P. Jajou, M. Brown, and L. Lisabeth Sex Differences in the Use of Intravenous rt-PA Thrombolysis Treatment for Acute Ischemic Stroke: A Meta-Analysis Stroke, May 1, 2009; 40(5): 1743 - 1749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Acker III, A. M. Pancioli, T. J. Crocco, M. K. Eckstein, E. C. Jauch, H. Larrabee, N. M. Meltzer, W. C. Mergendahl, J. W. Munn, S. M. Prentiss, et al. Implementation Strategies for Emergency Medical Services Within Stroke Systems of Care: A Policy Statement From the American Heart Association/ American Stroke Association Expert Panel on Emergency Medical Services Systems and the Stroke Council Stroke, November 1, 2007; 38(11): 3097 - 3115. [Full Text] [PDF]
|
|
|
|
 |
|
 G Citerio, D Galli, and A Pesenti Early stroke care in Italy--a steep way ahead: an observational study. Emerg. Med. J., August 1, 2006; 23(8): 608 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J van Oostenbrugge, R M M Hupperts, and J Lodder Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 375 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Part 4: Adult Basic Life Support Circulation, December 13, 2005; 112(24_suppl): IV-19 - IV-34. [Full Text] [PDF]
|
|
|
|
|
|
Part 9: Adult Stroke Circulation, December 13, 2005; 112(24_suppl): IV-111 - IV-120. [Full Text] [PDF]
|
|
|
|
|
|
Part 9: Stroke Circulation, November 29, 2005; 112(22_suppl): III-110 - III-104. [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Qureshi, J. F. Kirmani, M. A. Sayed, A. Safdar, S. Ahmed, R. Ferguson, L. A. Hershey, K. J. Qazi, and for the Buffalo Metropolitan Area and Erie County Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke Neurology, June 28, 2005; 64(12): 2115 - 2120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hill, A. M. Buchan, and for The Canadian Alteplase for Stroke Effectivenes Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study Can. Med. Assoc. J., May 10, 2005; 172(10): 1307 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Saposnik, F. Webster, C. O'Callaghan, and V. Hachinski Optimizing Discharge Planning: Clinical Predictors of Longer Stay After Recombinant Tissue Plasminogen Activator for Acute Stroke Stroke, January 1, 2005; 36(1): 147 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Lindsberg, L. Soinne, R. O. Roine, O. Salonen, T. Tatlisumak, M. Kallela, O. Happola, M. Tiainen, E. Haapaniemi, M. Kuisma, et al. Community-Based Thrombolytic Therapy of Acute Ischemic Stroke in Helsinki Stroke, June 1, 2003; 34(6): 1443 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nedeltchev, M. Arnold, C. Brekenfeld, J. Isenegger, L. Remonda, G. Schroth, and H. P. Mattle Pre- and In-Hospital Delays From Stroke Onset to Intra-arterial Thrombolysis Stroke, May 1, 2003; 34(5): 1230 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Merino, B. Silver, E. Wong, B. Foell, B. Demaerschalk, A. Tamayo, F. Poncha, and V. Hachinski Extending Tissue Plasminogen Activator Use to Community and Rural Stroke Patients Stroke, January 1, 2002; 33(1): 141 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gladstone and S. E. Black Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice Can. Med. Assoc. J., August 1, 2001; 165(3): 311 - 317. [Abstract] [Full Text] [PDF]
|
|